Lindsey H. M. te Brake

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Elin M. Svensson, Robin J. Svensson, Lindsey H. M. te Brake et al. · Clinical Infectious Diseases · 2018 · 100 citations · Full text

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis

R.E. Aarnoutse, Gibson Kibiki, Klaus Reither et al. · Antimicrobial Agents and Chemotherapy · 2017 · 89 citations · Full text

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg⁻¹rifampicin

Lindsey H. M. te Brake, Veronique de Jager, Kim Narunsky et al. · European Respiratory Journal · 2021 · 56 citations · Full text

Xpert MTB/RIF Ultra for the Diagnosis of Tuberculous Meningitis: A Small Step Forward

Joseph Donovan, Fiona V Cresswell, Nguyễn Thụy Thương Thương et al. · Clinical Infectious Diseases · 2020 · 46 citations · Full text

Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters

Lindsey H. M. te Brake, Frans G. M. Rüssel, Jeroen J. M. W. van den Heuvel et al. · Tuberculosis · 2015 · 44 citations

Pulmonary Tuberculosis, Biochemistry, Medicine +7